Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Completed 31Terminated 5Unknown 1

Sponsor Class

OTHER 9NIH 5INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 3Other solid neoplasm 1Gynecologic 1

Conditions

Breast Neoplasms 3Endometrial Neoplasms 1Advanced Solid Tumors 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × ixabepilone × Clear all
NCT04796324 2026-03-12

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Allarity Therapeutics

Phase 2 Terminated
13 enrolled 8 charts
Breast

Breast Neoplasms

NCT00883116 2017-03-09

IXAMPLE2

R-Pharm

Phase 3 Terminated
551 enrolled 13 charts
Gynecologic

Endometrial Neoplasms

NCT00546364 2016-03-10

IXTEND

R-Pharm

Phase 2 Terminated
62 enrolled 14 charts
Breast

Breast Neoplasms

NCT00632424 2016-03-10

Phase 1 Trial of Oral Ixabepilone

R-Pharm

Phase 1 Terminated
23 enrolled 11 charts
Other solid neoplasm

Advanced Solid Tumors

NCT00634088 2016-03-10

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

R-Pharm

Phase 1 Terminated
13 enrolled 13 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡